- Home
- ENTA vs PDLB Comparison
ENTA vs PDLB Comparison
Compare ENTA & PDLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- PDLB
- Stock Information
- Founded
- ENTA 1995
- PDLB 1960
- Country
- ENTA United States
- PDLB United States
- Employees
- ENTA N/A
- PDLB N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- PDLB
- Sector
- ENTA Health Care
- PDLB
- Exchange
- ENTA Nasdaq
- PDLB Nasdaq
- Market Cap
- ENTA 245.4M
- PDLB 256.3M
- IPO Year
- ENTA 2013
- PDLB 2017
- Fundamental
- Price
- ENTA $9.31
- PDLB $12.59
- Analyst Decision
- ENTA Buy
- PDLB
- Analyst Count
- ENTA 3
- PDLB 0
- Target Price
- ENTA $19.67
- PDLB N/A
- AVG Volume (30 Days)
- ENTA 114.1K
- PDLB 42.6K
- Earning Date
- ENTA 11-25-2024
- PDLB 10-30-2024
- Dividend Yield
- ENTA N/A
- PDLB N/A
- EPS Growth
- ENTA N/A
- PDLB N/A
- EPS
- ENTA N/A
- PDLB 0.37
- Revenue
- ENTA $71,960,000.00
- PDLB $79,488,000.00
- Revenue This Year
- ENTA N/A
- PDLB N/A
- Revenue Next Year
- ENTA $5.14
- PDLB $11.39
- P/E Ratio
- ENTA N/A
- PDLB $34.49
- Revenue Growth
- ENTA N/A
- PDLB 33.32
- 52 Week Low
- ENTA $8.51
- PDLB $7.89
- 52 Week High
- ENTA $17.80
- PDLB $13.15
- Technical
- Relative Strength Index (RSI)
- ENTA 28.86
- PDLB 58.61
- Support Level
- ENTA $10.84
- PDLB $12.52
- Resistance Level
- ENTA $10.89
- PDLB $13.15
- Average True Range (ATR)
- ENTA 0.49
- PDLB 0.32
- MACD
- ENTA -0.19
- PDLB 0.00
- Stochastic Oscillator
- ENTA 18.18
- PDLB 68.89
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About PDLB Ponce Financial Group Inc.
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.